TrialBlood advances2020

Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma.

Arne Kolstad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.